Missouri Mesothelioma Information | Surviving Mesothelioma

Mesothelioma in Missouri

While mesothelioma is a problem in all states, the specific incident rate for Missouri is 0.8 / 100,000. This is below the average rate of 1.1 / 100,000. Click on the tabs below to find mesothelioma and asbestos research in MO, recent MO mesothelioma-related court cases, mesothelioma specialists in MO and potential asbestos hotspots in Missouri.

Missouri Mesothelioma Info

By clicking on the above tabs, you will find information on mesothelioma specific to the state of Missouri

Missouri Research and Clinical Trials

This is a partial list of scientific or medical grants in your state for research into mesothelioma and related illnesses.

Missouri Doctors and Hospitals

This is a partial list of hospitals and physicians that reportedly treat mesothelioma patients in your state.

Missouri Cases

This is a partial list of relevant court cases on mesothelioma in your state.

Disclaimer: Inclusion on this directory does not constitute endorsement by Cancer Monthly, Inc. All physicians who appear in this section do so based on their own expression of interest in the fields of mesothelioma treatment. Cancer Monthly, Inc. has not verified the competence, professional credentials, business practices or validity of the expressed interests of these physicians. Cancer Monthly makes no recommendation of any physician on this list and makes no suggestion that any such physician will cure or prevent any disease. Those consulting a physician on this list should approach the consultation exactly as they would with any other unknown physician.

Research

Abstract: DESCRIPTION (adapted from the applicant’s abstract): Washington University has been a CALGB main member institution since 1986. Over the last five years, the cancer research program at the Washington University Medical Center (WUMC) has experienced tremendous growth. Barnes-Jewish Hospital, the largest hospital in St. Louis, diagnoses more than 5,400 patients a year with cancer and remains the major referral center for southeast Missouri and southern Illinois. The Siteman Cancer Center (SCC) at WUMC received NCI-designated Cancer Center status in August 2001. The infrastructure developed by the SCC to compete successfully for the NCI Cancer Center Support
Grant has significantly enhanced our ability to carry out all aspects of clinical cancer research, including cooperative group trials. Our recent efforts to expand institutional research studies will significantly enhance our ability to contribute concepts to CALGB during the next
Grant cycle, specifically in the areas of Hematologic malignancies, thoracic oncology, and pharmacogenomics. Between 1998 and 2002, 16 Washington University physicians and research assistants served on 36 different CALGB scientific and administrative committees. WUMC investigators chaired 12 CALGB studies, including Phase II studies in non-Hodgkin’s lymphoma, Hodgkin’s lymphoma, prostate cancer, mesothelioma, and several pharmacokinetic and pharmacogenomic correlative science studies. Six additional studies are in the final stages of development. Accrual to CALGB trials has continued to increase during this
Grant period, with an average of 183 patients per year registered to therapeutic and non-therapeutic trials from 1998 to 2001. Accrual to therapeutic trials increased from 61 patients in 1998 to 105 in 2001. Based on registrations to date, projected accrual to CALGB trials for 2002 is estimated to be 312, with 136 to therapeutic studies. Plans for the next
Grant cycle include 1) continued involvement by all current WUMC investigators, 2) increased participation by our Phase I investigators to facilitate development of Phase II studies within CALGB, 3) involvement of at least five additional WUMC investigators in CALGB activities including faculty interested in GU oncology, quality of life, stem cell transplant and leukemia, leukemia correlative sciences, and radiation oncology, and 5) continued efforts to increase accruals, particularly minority accruals, to CALGB trials. 

Tags: Combination Cancer Therapy, Combination Chemotherapy, Human Therapy Evaluation, Neoplasm /cancer Chemotherapy, Neoplasm /cancer Immunotherapy, Neoplasm /cancer Radiation Therapy, Neoplasm /cancer Surgery Aging, Antineoplastic, Breast Neoplasm, Cancer Prevention, Cancer Registry /resource, Cis Platinum Compound, Clinical Trial Phase I, Clinical Trial Phase Ii, Clinical Trial Phase Iii, Cooperative Study, Doxorubicin, Drug Resistance, Fluorouracil, Gastrointestinal Neoplasm, Health Care Cost /financing, Hormone Therapy, Irinotecan, Leucovorin, Leukemia, Lymphoma, Melanoma, Neoplasm /cancer Diagnosis, Neoplasm /cancer Epidemiology, Neoplasm /cancer Genetics, Neoplasm /cancer Pharmacology, Oncology Nursing, Paclitaxel, Pathology, Prostate Neoplasm, Psychological Aspect Of Cancer, Quality Of Life, Respiratory Neoplasm, Tamoxifen, Thorax Neoplasm, Urinary Tract Neoplasm Clinical Research, Human Subject, Patient Oriented Research 

  • Followup
    Grant:
     5U10CA077440-07
  • Followup
    Grant:
     5U10CA077440-08
  • Followup
    Grant:
     5U10CA077440-09
  • Followup
    Grant:
     5U10CA077440-10
  • Followup
    Grant:
     5U10CA077440-11

Abstract: The long-term goals of this proposal are to understand both at the level of the gene and the protein mechanisms by which cells are stimulated to proliferate in normal growth and in development and in the abnormal regulatory mechanisms that lead to aberrant growth in transformed cell growth and tumors. This proposal now seeks to continue the analysis of the regulation of the PDGF A-chain gene, a gene that encodes a potent growth regulatory factor that is highly developmentally regulated and overexpressed in selected transformed cell lines. It is planned to identify and characterize regulatory sequences within 5′ flanking region and within the first intron of the PDGF A-chain gene that are important in developmental stage and cell type specificity of expression. Any elements that are identified will be characterized and proteins that interact with these elements and that mediate in trans the function of these elements will be cloned and characterized. It is planned to use any cell type specific enhancers identified to direct dominant negative mutations to generate cell type specific loss of endogenous PDGF. A function in the transgenic mouse. It is planned to use the activation and repressor domains identified in the product of the Wilms’ tumor gene to further analyze the mechanisms by which the Wilms’ tumor gene influences transcription of the PPDGF A-chain gene, to identify proteins that dimerize with or otherwise interact with WTI to influence transcription of the PDGF A-chain gene, and to seek the function of the +17AA alternatively spliced insert of WT1 on transcription of the PDGF A-chain gene. To seek the potential relevance of WT1 on transcription of the PDGF A-chain gene, we will transfect positive and negative regulatory domains of WT1 into mesothelioma cells that express high levels of both PDGF A and WT1 and mesothelial cells that are transformed with PDGF A. The phenotypes of these cells will be characterized and transcriptional activity of each gene will be tested. It is planned to characterize and clone proteins for the repressor activity of methylation on transcription of the PDGF A-chain gene and to use methods of Southern blotting and genomic sequencing to seek direct evidence for methylation of the PDGF A chain gene in specific tissues and in selected times of development and in tumors. It is then planned to seek the role of methylation on transcription of the PDGF A- chain gene in selected cell lines. The Project will use established techniques of biochemistry and molecular and cell biology. It will utilize also the Core Projects and interactions among investigators of the Program Project to advance each of the Specific Aims. It is hoped that the results of this research will identify genetic mechanisms that serve to regulate expression of the PDGF A-chain gene and the consequences of its regulation in tumor cells and to identify sites and strategies for modifying the function and contributions of the PDGF A-chain to cancer cell growth. 

Tags: Cell Growth Regulation, Genetic Regulation, Intron, Neoplasm /cancer Genetics, Neoplastic Transformation, Platelet Derived Growth Factor Dna Binding Protein, Dna Methylation, Wilms’ Tumor, Developmental Genetics, Gene Expression, Genetic Promoter Element, Genetic Regulatory Element, Genetic Transcription, Nucleic Acid Sequence, Reporter Gene, Transcription Factor, Tumor Suppressor Gene Athymic Mouse, Laboratory Mouse, Molecular Cloning, Transgenic Animal 

  • Followup
    Grant:
     7P01CA049712-090002
  • Followup
    Grant:
     5P01CA049712-100002

Clinical Trials

Condition: Malignant Mesothelioma
Intervention: Drug: gefitinib
More Information

Condition: Malignant Mesothelioma
Intervention: Drug: vatalanib
More Information

Condition: Malignant Mesothelioma
Intervention: Drug: erlotinib hydrochloride
More Information

Condition: Malignant Mesothelioma
Intervention: Drug: cediranib maleate
More Information

Condition: Malignant Mesothelioma
Intervention: Drug: cisplatin;   Drug: gemcitabine hydrochloride
More Information

Condition: Malignant Mesothelioma
Intervention: Drug: capecitabine
More Information

Condition: Malignant Mesothelioma
Intervention: Drug: dasatinib;  
Other: immunoenzyme technique;   Other: immunohistochemistry staining method;  
Other: laboratory biomarker analysis

More Information

Condition: Malignant Mesothelioma
Intervention: Drug: sorafenib tosylate
More Information

Condition: Malignant Mesothelioma
Intervention: Drug: doxorubicin hydrochloride;   Drug: ranpirnase
More Information

Condition: Malignant Mesothelioma
Intervention: Drug: everolimus
More Information

Condition: Malignant Mesothelioma
Intervention: Drug: pazopanib hydrochloride;   Other: laboratory biomarker analysis
More Information

Condition: Malignant Mesothelioma
Intervention: Drug: epirubicin hydrochloride;   Drug: gemcitabine hydrochloride
More Information

Condition: Cancer
Intervention: Other: biologic sample preservation procedure
More Information

Hospital and Cancer Centers

Veterans Affairs Medical Center-Columbia (Truman Memorial)
800 Hospital Drive
Columbia, MO
573.814.6000

Cases

Hoskins v. Business Men’s Assur.
No. SC83727, SUPREME COURT OF MISSOURI, July 23, 2002, Filed

State ex rel. Ford Motor Co. v. Nixon
WD67518 , COURT OF APPEALS OF MISSOURI, WESTERN DISTRICT, April 24, 2007, Opinion Filed

H.K. Porter Co. v. Transit Cas. Co.
WD 66076 , COURT OF APPEALS OF MISSOURI, WESTERN DISTRICT, October 31, 2006, Opinion Filed

Goede v. Aerojet Gen. Corp.
No. ED82833 , COURT OF APPEALS OF MISSOURI, EASTERN DISTRICT, DIVISION THREE, May 11, 2004, Opinion Filed

Hoskins v. Business Men’s Assur.
WD 61744 , COURT OF APPEALS OF MISSOURI, WESTERN DISTRICT, June 30, 2003, Opinion Filed

Baby-Tenda Corp. v. Stacey Marie Hedrick & Div. of Empl. Sec.
WD 59050, COURT OF APPEALS OF MISSOURI, WESTERN DISTRICT, July 24, 2001, Filed

Lawyers

If you would like information on how to see the published ratings for different mesothelioma lawyers and law firms, please fill-in the form below:

[contact-form-7 id=”372″ title=”Occupation”]

Get your free copy of
“Surviving Mesothelioma” Today!